Integrins and Actions of Androgen in Breast Cancer.
PD-L
androgen
androgen receptor
breast cancer
integrin αvβ3
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
22 08 2023
22 08 2023
Historique:
received:
05
07
2023
revised:
16
08
2023
accepted:
19
08
2023
medline:
11
9
2023
pubmed:
8
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
Androgen has been shown to regulate male physiological activities and cancer proliferation. It is used to antagonize estrogen-induced proliferative effects in breast cancer cells. However, evidence indicates that androgen can stimulate cancer cell growth in estrogen receptor (ER)-positive and ER-negative breast cancer cells via different types of receptors and different mechanisms. Androgen-induced cancer growth and metastasis link with different types of integrins. Integrin αvβ3 is predominantly expressed and activated in cancer cells and rapidly dividing endothelial cells. Programmed death-ligand 1 (PD-L1) also plays a vital role in cancer growth. The part of integrins in action with androgen in cancer cells is not fully mechanically understood. To clarify the interactions between androgen and integrin αvβ3, we carried out molecular modeling to explain the potential interactions of androgen with integrin αvβ3. The androgen-regulated mechanisms on PD-L1 and its effects were also addressed.
Identifiants
pubmed: 37681860
pii: cells12172126
doi: 10.3390/cells12172126
pmc: PMC10486718
pii:
doi:
Substances chimiques
Androgens
0
B7-H1 Antigen
0
Integrin alphaVbeta3
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Horm Cancer. 2013 Dec;4(6):335-42
pubmed: 23943159
Front Immunol. 2020 Oct 21;11:568931
pubmed: 33193345
Mol Endocrinol. 2003 May;17(5):870-81
pubmed: 12554777
J Biomed Sci. 2022 Jun 15;29(1):41
pubmed: 35705962
Cancer Res. 2023 Feb 3;83(3):456-470
pubmed: 36469363
Endocrinology. 1997 Apr;138(4):1406-12
pubmed: 9075695
Cancers (Basel). 2021 Jan 27;13(3):
pubmed: 33513758
Cancer Biol Med. 2021 Oct 09;:
pubmed: 34623791
Oncogene. 2005 Jul 7;24(29):4660-71
pubmed: 15897907
Neoplasia. 2008 Jun;10(6):542-8
pubmed: 18516291
Cancer Biol Ther. 2015;16(1):52-9
pubmed: 25427201
Mol Cancer. 2014 Sep 08;13:208
pubmed: 25200184
Adv Protein Chem Struct Biol. 2019;116:135-170
pubmed: 31036290
Cancer Lett. 2014 Aug 28;351(1):64-71
pubmed: 24944078
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006478
pubmed: 22229119
J Cell Physiol. 2010 Jan;222(1):156-67
pubmed: 19780039
Physiol Rev. 2021 Jan 1;101(1):319-352
pubmed: 32584192
Genome Biol. 2007;8(5):215
pubmed: 17543136
Int J Cancer. 2006 Feb 15;118(4):889-98
pubmed: 16152594
Mol Med. 2007 Jan-Feb;13(1-2):79-88
pubmed: 17515959
Int J Mol Sci. 2023 Mar 29;24(7):
pubmed: 37047395
Cancer Res. 2016 Sep 1;76(17):5163-74
pubmed: 27450452
J Mol Endocrinol. 2004 Jun;32(3):793-810
pubmed: 15171713
Histopathology. 2023 Apr;82(5):664-671
pubmed: 36527253
Exp Cell Res. 2001 Apr 1;264(2):307-14
pubmed: 11262187
J Extracell Vesicles. 2022 Aug;11(8):e12234
pubmed: 35923105
Biomed Pharmacother. 2021 Jun;138:111436
pubmed: 33667790
Oncogene. 2021 Feb;40(6):1043-1063
pubmed: 33420366
Mol Endocrinol. 2014 Jun;28(6):935-48
pubmed: 24739041
Cancer Metastasis Rev. 2010 Mar;29(1):207-22
pubmed: 20111892
EMBO J. 2000 Oct 16;19(20):5406-17
pubmed: 11032808
PLoS One. 2011 Jan 14;6(1):e15942
pubmed: 21264241
Mol Med Rep. 2018 Jun;17(6):8203-8211
pubmed: 29658587
Cell Death Dis. 2020 Jul 6;11(7):506
pubmed: 32632098
Anticancer Res. 2005 Jan-Feb;25(1A):79-83
pubmed: 15816522
NPJ Breast Cancer. 2016 Feb 24;2:16002
pubmed: 28721372
Carcinogenesis. 2021 Feb 11;42(1):38-47
pubmed: 32832992
FEBS J. 2013 May;280(10):2207-15
pubmed: 23375101
Endocr Relat Cancer. 2016 Oct;23(10):R485-98
pubmed: 27528625
PLoS One. 2013 Oct 09;8(10):e76899
pubmed: 24130806
PLoS One. 2013 Oct 09;8(10):e76513
pubmed: 24130778
Oncogene. 2008 Aug 28;27(37):5057-68
pubmed: 18504439
Int J Mol Sci. 2020 Apr 21;21(8):
pubmed: 32326308
PLoS One. 2021 Jan 22;16(1):e0244985
pubmed: 33481853
Curr Oncol Rep. 2015 Feb;17(2):4
pubmed: 25665553
Gland Surg. 2020 Dec;9(6):2106-2115
pubmed: 33447561
Mol Cancer Ther. 2014 May;13(5):1067-77
pubmed: 24674886
Int J Endocrinol. 2015;2015:294278
pubmed: 26491440
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
Cancers (Basel). 2022 Jan 12;14(2):
pubmed: 35053528
BMC Cancer. 2014 Apr 23;14:283
pubmed: 24758408
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Cancer Res. 2014 Mar 1;74(5):1598-608
pubmed: 24385215
Steroids. 2016 Oct;114:41-47
pubmed: 27394959
PLoS One. 2014 Jan 31;9(1):e86238
pubmed: 24497940
J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):52-8
pubmed: 16797178
Oncogene. 2021 Apr;40(15):2667-2681
pubmed: 33692467
Cell Biochem Biophys. 2010 Sep;58(1):31-44
pubmed: 20652762
Clin Cancer Res. 2016 Apr 15;22(8):1969-77
pubmed: 26573597
Cancer Res. 2002 May 1;62(9):2699-707
pubmed: 11980671
Methods Mol Biol. 2012;757:369-97
pubmed: 21909923
Cancer Biol Ther. 2022 Dec 31;23(1):173-185
pubmed: 35188070
J Biol Chem. 2023 Jan;299(1):102725
pubmed: 36410437
Ann N Y Acad Sci. 2006 Nov;1089:194-200
pubmed: 17261767
Acta Pharmacol Sin. 2022 Feb;43(2):429-445
pubmed: 33824459
Mol Cell Endocrinol. 2006 Jul 11;253(1-2):36-43
pubmed: 16723184
Cell Adh Migr. 2013 May-Jun;7(3):251-61
pubmed: 23563505
Cell Physiol Biochem. 2007;20(6):977-86
pubmed: 17982280
Oncol Rep. 2009 Aug;22(2):327-35
pubmed: 19578773
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
J Steroid Biochem Mol Biol. 1995 May;52(5):459-67
pubmed: 7748811
Am J Transl Res. 2020 Apr 15;12(4):1428-1442
pubmed: 32355552
Sci Rep. 2022 Nov 7;12(1):18879
pubmed: 36344556
Oncogene. 2020 Jul;39(31):5390-5404
pubmed: 32565538
Science. 2002 Apr 5;296(5565):151-5
pubmed: 11884718
Sci Rep. 2019 Mar 14;9(1):4490
pubmed: 30872694
Breast Cancer Res. 2020 Dec 4;22(1):136
pubmed: 33276802
PLoS One. 2014 Feb 14;9(2):e88557
pubmed: 24551119
Genes Dis. 2018 May 12;5(2):77-106
pubmed: 30258937
Cell Death Dis. 2019 Sep 9;10(9):649
pubmed: 31501409
PLoS One. 2012;7(8):e41613
pubmed: 22927910
Oncol Res Treat. 2017;40(5):294-297
pubmed: 28346916
J Steroid Biochem Mol Biol. 2019 Sep;192:105406
pubmed: 31185279
J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):182-8
pubmed: 19159686
Urol Int. 2008;81(3):353-9
pubmed: 18931557
Cells. 2020 Aug 03;9(8):
pubmed: 32756527
J Physiol. 2009 Nov 1;587(Pt 21):5019-23
pubmed: 19687123
Endocrinology. 2000 Sep;141(9):3172-82
pubmed: 10965888
Nat Commun. 2021 Sep 1;12(1):5209
pubmed: 34471106
Breast Cancer Res. 2023 Jan 31;25(1):13
pubmed: 36721218
Nat Med. 2021 Feb;27(2):310-320
pubmed: 33462444
Am J Clin Pathol. 2003 Nov;120(5):725-31
pubmed: 14608899
Int J Nanomedicine. 2017 Oct 27;12:7913-7921
pubmed: 29138558
J Biomed Res. 2011 Jul;25(4):237-45
pubmed: 23554696
J Biol Chem. 2009 Dec 4;284(49):33966-81
pubmed: 19837659
Biochem Soc Trans. 2000;28(4):311-39
pubmed: 10961914
Oncotarget. 2015 Nov 3;6(34):35866-79
pubmed: 26456774
Breast Cancer Res. 2021 Nov 4;23(1):102
pubmed: 34736512
J Carcinog. 2011;10:20
pubmed: 21886458
Elife. 2022 Mar 14;11:
pubmed: 35285795
RSC Adv. 2019 Feb 15;9(10):5682-5691
pubmed: 35515929
Cell Death Dis. 2022 Feb 8;13(2):123
pubmed: 35136023
Front Cell Dev Biol. 2022 Feb 14;10:829788
pubmed: 35237605
Mol Cancer. 2022 Jun 29;21(1):138
pubmed: 35768871
J Clin Invest. 1995 Oct;96(4):1815-22
pubmed: 7560073
BMC Urol. 2008 Apr 23;8:7
pubmed: 18433501
Mod Pathol. 2010 May;23(5):644-53
pubmed: 20208479
Breast Cancer Res. 2015 Feb 25;17:28
pubmed: 25849225
Endocrinology. 2002 Oct;143(10):3897-904
pubmed: 12239101
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7589-94
pubmed: 15897451
Breast Cancer (Dove Med Press). 2016 May 20;8:93-107
pubmed: 27284266
J Pathol. 2015 Apr;235(5):760-72
pubmed: 25430721
J Biol Chem. 2013 Jul 5;288(27):19593-603
pubmed: 23696648
Oncogene. 2006 Jun 29;25(28):3994-4008
pubmed: 16491124
Am J Clin Exp Urol. 2019 Aug 15;7(4):297-312
pubmed: 31511835
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166